TrialBreast cancer research : BCR2017

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.

Stephen K Chia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.